Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Glycoprotein – e.g. – mucins – proteoglycans – etc.
Reexamination Certificate
2000-03-21
2001-06-05
Stucker, Jeffrey (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Glycoprotein, e.g., mucins, proteoglycans, etc.
C530S388750, C530S827000, C530S501000, C435S343100, C435S372000
Reexamination Certificate
active
06242579
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a novel monoclonal antibody recognizing a small subset of human hematopoietic cells, which may include the hematopoietic stem cell population.
BACKGROUND OF THE INVENTION
Hematopoietic stem cells are defined as those cells that are capable of both self-renewal and differentiation into the two principle precursor components—the myeloid and lymphoid lines. Such stem cells are said to be “totipotent.” Stem cells that are less general but that can still differentiate into several lines are called “pluripotent.” Further differentiation then occurs among the precursor cells to produce the monocyte, eosinophil, neutrophil, basophil, megakaryocytes, and erythroid lineages from the myeloid line, and T cells, B cells, and NK cells from the lymphoid line. For a background review of the stem cell see
Scientific American
256:86-93 (December 1991).
One of the first breakthroughs into stem cell isolation and identification came in the late 1980's. In U.S. Pat. No. 4,714,680 (Dec. 22, 1987), Civin described a population of pluripotent lympho-hematopoietic cells that were substantially free of mature lymphoid and myeloid cells. Civin also described an antigen, MY-10, and a monoclonal antibody thereto, which was present on those cells. Those cells made up about 1% of all cells in normal adult bone marrow, and generally comprised a mixture of totipotent, and pluripotent stem cells and lineage committed precursor cells with the latter cells predominating.
Since that time, MY-10 has been classified by the International Workshop on Human Leukocyte Antigens as falling with the cluster designated as “CD34.” Anti-CD34 monoclonal antibodies are now commercially available from a number of sources including, for example, Becton Dickinson Immunocytometry Systems (“BDIS”).
Anti-CD34 monoclonal antibodies have been used for a number of purposes. Loken, Terstappen and their collaborators have published a series of papers describing the maturational stages for various components of the hematopoietic system, such as B lymphocytes (Loken et al.,
Blood
70:1316-1324 (November 1987)), erythroid cells (Loken et al.,
Blood
69:255-263 (January 1987)), and neutrophils (Terstappen et al.,
Leukemia
4:657-663 (September 1990)). The objective of these studies was to define, starting from the most mature cell and working backwards, the various maturational and developmental stages of a lineage committed cell.
Anti-CD34 monoclonal antibodies have also been used to look for earlier non-lineage committed stem cells. For example, Terstappen et al.,
Blood
77:1218-1227 (March 1991), described a subset of human progenitor cells that were capable of self-renewal and differentiation into each of the various hematopoietic lineages (i.e., a population of cells that include cells that are totipotent). This population was characterized as being CD34
+
/CD38
−
.
U.S. Pat. No. 5,061,620 to Tsukamoto et al. (Oct. 29, 1991) also described a population of cells that were capable of self-renewal and differentiation. This population of cells was characterized as being CD34
+
/CD10
−
/CD19
−
/CD33
−
and Thy-1
+
.
Other investigators have attempted to subset CD34
+
cells from both peripheral blood and bone marrow. Bender et al.,
Blood
77:2591-2596 (June 1991), used four color flow cytometry with combinations of monoclonal antibodies (i.e., anti-CD34, anti-CD33, anti-CD45, anti-CD19, anti-CD7, anti-CD10, anti-CD3, anti-CD20, anti-CD14, anti-CD11b and anti-HLA-DR), to identify and isolate CD34
+
hematopoietic progenitor cells. Bender et al. were able to identify a number of subsets. One subset was CD34
+
/HLA-DR-. This subset had a very small number of cells and no clear population of this phenotype was resolved. Bender et al. speculated on the ability of this population of cells to give rise to blast cell colonies or cells reconstituting long term cultures based upon prior work of others.
Sutherland et al.,
Blood
78:666-672 (August 1991), reported on the differential regulation of “primitive” hematopoietic cells in long term culture. They used anti-CD34 and anti-HLA-DR monoclonal antibodies to select cells that were CD34
+
and HLA-DR
dim
or HLA-DR
−
. These cells were then grown on a unique stromal cell line. The purpose of this work was to establish a method of long term culture of such cells for the purposes of studying hematopoiesis and the effect of different growth factors on hematopoiesis.
Simmons et al.,
Blood
78:55-62 (July 1991), also reported on the “identification” of a stromal cell precursor in human bone marrow. Using an antibody they designated “Stro-1,” Simmons et al. were able to remove stromal cells from bone marrow. The antigen recognized by this antibody was not present on colony forming progenitor cells but was present on a “subpopulation of cells experiencing the [CD34] antigen.” Thus, Simmons et al. described the ability of the antibody to separate out stromal cells from hematopoietic cells in bone marrow before culture.
Verfaillie et al.,
J. Exp. Med.
172:509-520 (August 1990), reported on a CD34
+
/HLA-DR
+
and CD34
+
/HLA-DR
−
population of“primitive” progenitor cells. Taking adult marrow, Verfaille et al. depleted bone marrow of lineage
+
cells using multiple monoclonal antibodies. Next, fluorescently labeled CD34 and HLA-DR monoclonal antibodies were used to select HLA-DR
+
and HLA-DR
−
populations that were also CD34
+
. Having isolated these two groups, Verfaille et al. reported that the HLA-DR
+
cells were better in short term culture than the HLA-DR
−
cells. In long term culture, the reverse was true.
WO93/25216, published Dec. 23, 1993, teaches a population of human primitive stem cells that are capable of self-renewal and that are capable of differentiating into hematopoietic stem cells and stromal stem cells that give rise to the hematopoietic microenvironment. This population of cells has the phenotype CD34
+
/CD38/HLA-DR. This population of cells lacks lineage committed antigens (i.e., is CD33-, CD10-, CD5-, and CD71-). Cells having this phenotype were identified in adult and fetal peripheral blood, bone marrow, thymus, liver, or spleen using a combination of antibodies and selecting for the presence or absence of the antigens recognized by these antibodies on the cells. Preferably, the combination of antibodies comprised at least three monoclonal antibodies and more preferably comprised anti-CD34, anti-CD38 and anti-HLA-DR monoclonal antibodies.
WO94/02157, published Feb. 3, 1994, teaches the isolation of human hematopoietic stem cells that are CD34
+
, HLA-DR and express the receptor for the c-kit ligand (KR
+
). This cell population was reportedly useful for transplantation and in gene therapy protocols.
To date, the CD34 antigen, as identified by monoclonal antibodies, has been the only known cell surface marker to be used to define the hematopoietic stem cell compartment and has become the marker of choice not only for the identification of stem cells but also for their isolation. Published information now indicates the existence of monoclonal antibodies that define cell surface markers distinct from CD34; (i) monoclonal antibody AC133 which binds to a surface protein of 96 kDa on approximately 50% of CD34
+
cells; (ii) monoclonal antibody BB9 which binds to a surface protein of 160 kDa on approximately 10-28% of CD34
+
cells; and (iii) a non-designated monoclonal antibody that binds to a glycoprotein 105 on the surface of hematopoietic stem cells. Virtually all of the CFU-S and colony forming unit cells detectable by in vitro stem cell assays express the CD34 antigen. Furthermore, a number of animal and human studies have demonstrated that purified CD34
+
cells are capable of reconstituting the entire hematopoietic system, suggesting that early engraftment by progenitor cells and long-term maintenance by primitive stem cells are mediated by this population
Lawman Michael J. P.
Lawman Patricia
Saliwanchik Lloyd & Saliwanchik
Stucker Jeffrey
LandOfFree
Antigen found on a small subset of human hematopoietic cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen found on a small subset of human hematopoietic cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen found on a small subset of human hematopoietic cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2540285